Physician profile
David J Sinclair
NPI 1235391046
$4,623.00
in general payments reported to CMS, 2019-2025
27 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.97 · 2021: $47.55 · 2022: $355 · 2023: $970 · 2024: $1,494 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,196.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $720.74 | 2022-2025 | Kisunla, Emgality, Amyvid |
| Eisai INC. | $480.41 | 2023-2025 | |
| Lundbeck LLC | $379.37 | 2022-2025 | Vyepti |
| Abbvie INC. | $354.04 | 2023-2025 | Ubrelvy, Qulipta, Duopa |
| Acadia Pharmaceuticals INC | $334.19 | 2024-2025 | Nuplazid |
| Amylyx Pharmaceuticals, INC. | $282.64 | 2023-2024 | Relyvrio |
| Argenx US, INC. | $196.79 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Janssen Biotech, INC. | $193.94 | 2025 | |
| Genentech USA, INC. | $191.41 | 2022-2025 | Ocrevus, Evrysdi, Tnkase |
| Alexion Pharmaceuticals, INC. | $159.55 | 2024-2025 | Ultomiris |
| Ceribell, INC. | $158.79 | 2025 | Pocket Eeg Device |
| Merz Pharmaceuticals, LLC | $157.27 | 2021-2024 | Xeomin, Inbrija |
| Silk Road Medical, INC. | $143.70 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Biogen, INC. | $123.99 | 2022-2025 | Leqembi |
| Acorda Therapeutics, INC | $119.57 | 2019-2023 | Inbrija, Ampyra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $111.01 | 2022-2025 | Rystiggo |
| Teva Pharmaceuticals USA, INC. | $76.29 | 2022-2024 | Austedo Xr, Ajovy |
| Csl Behring | $72.98 | 2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $72.48 | 2024 | |
| Vanda Pharmaceuticals INC. | $65.18 | 2022-2025 | Ponvory |
| Amgen INC. | $56.63 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $49.79 | 2025 | |
| Tanabe Pharma America, INC. | $31.76 | 2022 | |
| Amneal Pharmaceuticals LLC | $29.45 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.19 | 2022 | |
| Boston Scientific Corporation | $18.80 | 2025 | Wavewriter Alpha Prime 16 |
| Corium, LLC | $18.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.